血清Tracp5b在乳腺癌骨转移诊断和治疗效果监测方面的临床价值

摘要

目的:探讨血清抗酒石酸酸性磷酸酶5b(tartrate-resistant acid phosphatase 5b,Tracp5b)在诊断乳腺癌骨转移以及评价乳腺癌骨转移治疗效果方面的价值.方法:采用酶联免疫吸附法(enzyme-linked immumosorbent assay,ELISA)检测30例无骨转移乳腺癌患者及22例乳腺癌骨转移患者的血清Tracp5b水平,并检测骨转移患者应用化疗或内分泌治疗同时加用双膦酸盐治疗4个月后血清Tracp5b水平,对检测结果的差异性进行比较.结果:相对于乳腺癌无骨转移组,骨转移组血清Tracp5b的水平明显升高,差异有统计学意义(P＜0.05);在化疗或内分泌治疗同时加用双膦酸盐治疗4个月后,骨转移组患者的血清Tracp5b水平明显下降,差异有统计学意义(P＜0.05).结论:血清Tracp5b在发生乳腺癌骨转移时明显升高,在治疗显效后显著下降,Tracp5b可作为诊断乳腺癌骨转移和评价乳腺癌骨转移治疗效果的血清学指标.%Objective:To discuss the clinical value of serum tartrate-resistant acid phosphatase 5b(Tracp5b) as a marker in diagnosing bone metastases and evaluating the therapeutic efficacy in breast cancer patients.Methods:The serum levels of Tracp5b were determined by enzyme-linked immumosorbent assay(ELISA) in 30 breast cancer patients without bone metastases and 22 breast cancer patients with bone metastases.The 22 cases with bone metastases were detected again after chemical treatment or endocrine therpy while adding 4 months treatment of bisphosphonate.Results:The serum levels of Tracp5b in breast cancer patients with bone metastases were significantly higher than patients without bone metastases (P ＜ 0.05).The serum levels of Tracp5b in breast cancer patients with bone metastases decreased significantly after four months treatment (P ＜ 0.05).Conclusion:TracpSb is a useful marker to diagnose bone metastases in breast cancer patients and evaluate the therapeutic efficacy of bisphosphonate.